Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and <i>Mycoplasma hyopneumoniae</i> When Administered at 3 Weeks of Age

Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and <i>Mycoplasma hyopneumoniae</i> When Administered at 3 Weeks of Age

This study aimed to evaluate the efficacy of a new trivalent vaccine containing inactivated Porcine Circovirus 1-2a and 1-2b chimeras and a <i>Mycoplasma hyopneumoniae</i> bacterin administered to pigs around 3 weeks of age. This trivalent vaccine has already been proved as efficacious i...

Full description

Bibliographic Details
Main Authors: Patricia Pleguezuelos, Marina Sibila, Carla Ramírez, Rosa López-Jiménez, Diego Pérez, Eva Huerta, Anna Maria Llorens, Mónica Pérez, Florencia Correa-Fiz, José Carlos Mancera Gracia, Lucas P. Taylor, Jennifer Smith, Meggan Bandrick, Stasia Borowski, Gillian Saunders, Joaquim Segalés, Sergio López-Soria, Maria Fort, Mónica Balasch
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Vaccines
Subjects:
porcine circovirus 2
postweaning multisystemic wasting disease
porcine respiratory disease complex
trivalent vaccine
efficacy
single dose
Online Access:https://www.mdpi.com/2076-393X/10/12/2108

Similar Items

Similar Items